Cytovance Biologics, Inc., a contract manufacturing organization (CMO) of mammalian and microbial biologics, is extending its manufacturing agreement with Precision Biologics, Inc., a Texas-based clinical-stage biopharmaceutical company.  

Precision Biologics is advancing its clinical trials with a monoclonal antibody candidate, ensituximab or NEO-102 – which is being developed as a therapeutic drug candidate for pancreatic and colorectal cancers.  Precision has contracted Cytovance Biologics as its CMO to provide technology transfer and additional cGMP manufacturing services of NEO-102 in support of its ongoing Phase II clinical trials.

Source: Cytovance Biologics